Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

Harold J. Burstein; Martine J. Piccart-Gebhart; Edith A. Perez; Gabriel N. Hortobagyi; Norman Wolmark; Kathy S. Albain; Larry Norton; Eric P. Winer; Clifford A. Hudis

doi:10.1200/JCO.2012.42.0695

Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

Harold J. Burstein, Martine J. Piccart-Gebhart, Edith A. Perez, Gabriel N. Hortobagyi, Norman Wolmark, Kathy S. Albain, Larry Norton, Eric P. Winer, Clifford A. Hudis

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Comment/debate › peer-review

33 Scopus citations

Original language	English (US)
Pages (from-to)	2179-2182
Number of pages	4
Journal	Journal of Clinical Oncology
Volume	30
Issue number	18
DOIs	https://doi.org/10.1200/JCO.2012.42.0695
State	Published - Jun 20 2012

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2012.42.0695

Cite this

@article{cce5b24db121489fa1e7f9dfbfbd17c8,

title = "Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?",

author = "Burstein, {Harold J.} and Piccart-Gebhart, {Martine J.} and Perez, {Edith A.} and Hortobagyi, {Gabriel N.} and Norman Wolmark and Albain, {Kathy S.} and Larry Norton and Winer, {Eric P.} and Hudis, {Clifford A.}",

year = "2012",

month = jun,

day = "20",

doi = "10.1200/JCO.2012.42.0695",

language = "English (US)",

volume = "30",

pages = "2179--2182",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "18",

}

TY - JOUR

T1 - Choosing the best trastuzumab- based adjuvant chemotherapy regimen

T2 - Should we abandon anthracyclines?

AU - Burstein, Harold J.

AU - Piccart-Gebhart, Martine J.

AU - Perez, Edith A.

AU - Hortobagyi, Gabriel N.

AU - Wolmark, Norman

AU - Albain, Kathy S.

AU - Norton, Larry

AU - Winer, Eric P.

AU - Hudis, Clifford A.

PY - 2012/6/20

Y1 - 2012/6/20

UR - http://www.scopus.com/inward/record.url?scp=84864018416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864018416&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.42.0695

DO - 10.1200/JCO.2012.42.0695

M3 - Comment/debate

C2 - 22614986

AN - SCOPUS:84864018416

SN - 0732-183X

VL - 30

SP - 2179

EP - 2182

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 18

ER -

Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this